



## Additional file 1: Figures S1-S12

**Figure S1:**




**Figure S1:** Distribution of GFP expression in the *MommeD41* colony. The percentage of red blood cells expressing GFP was assessed in 107 mice from the *MommeD41* colony at weaning, and grouped by genotype for the *Morc3* mutation. Wild types are shown in blue and heterozygotes are shown in orange.

**Figure S2:**




**Figure S2:** Characterization of *Morc3*<sup>MD41/MD41</sup> mESCs (MommeD line). **a** Representative images of cellular morphology and alkaline phosphatase (AP) staining of the WT and the *Morc3*<sup>MD41/MD41</sup> derived mESCs grown in 2i and serum. **b** Pluripotent gene expression levels in WT and the *Morc3*<sup>MD41/MD41</sup>. Error bars represent 1 standard deviation. **c** RNA-seq validates the downregulation of *Morc3* in *Morc3*<sup>MD41/MD41</sup>. Error bars represent 1 standard deviation.

**Figure S3:**




**Figure S3:** Characterization of *Morc3*<sup>-/-</sup> mESCs (CRISPR line). **a** Sanger sequencing shows a 58-bp deletion in exon 2 of *Morc3* gene. **b** Genome browser shot of mapped RNAseq reads shows absence of exon 2 in the *Morc3*<sup>-/-</sup> mutant lines. **c** Western blot in *Morc3*<sup>-/-</sup> and WT mESC lines shows absence of MORC3 protein in the mutant line. **d** Pluripotent gene expression levels in WT and the *Morc3*<sup>-/-</sup>. Error bars represent 1 standard deviation.

**Figure S4:**



**Figure S4:** MORC3 enrichment at IAPEz-ints in WT mESCs (left) and *Morc3*<sup>-/-</sup> mESCs (right).


**Figure S5**



**Figure S5:** Boxplots comparing the length of TEs bound by MORC3 with the length of all TEs in that subfamily.


Mann–Whitney U test was used to test for significance (p-value =  $9.33e-48$  for IAPEz-int, p-value =  $3.2e-68$  for RLTR27, p-value =  $2e-11$  for LTRIS2, p-value = 0.5 for IAPLTR1a\_Mm and p-value =  $1.4e-05$  for IAPA\_MM-int)

**Figure S6**




**Figure S6:** Coverage of MORC3, H3K4me3 and H3K9me3 at MORC3 bound promoters (**a**) and at IAPÉz-int (**b**).

**Figure S7**



**Figure S7:** MORC3 ChIP-qPCR to validate the presence of MORC3 at the *Cdca7* promoter, at exon 1 of *Gapdh* and at an IAPLTR2a. RLTRETN\_Mm, ORR1B2-int, *Gapdh* exon6 and *Dpp6* intron are loci where MORC3 is absent and were used as negative control for MORC3 ChIP-qPCR.


**Figure S8:**



**Figure S8:** Distribution of MORC2A ChIP-seq peaks over genomic features.




**Figure S9:**



**Figure S9:** Heatmaps showing the enrichment of H3K9me3 over TEs in MommeD and CRISPR lines.


**Figure S10:**



**Figure S10:** **a** Meta plot and heatmaps showing enrichment of ATAC-seq read coverage around TSS of mouse genes. Coverage is measured in rpkM. **b** Metaplot and heatmaps showing the enrichment of TRIM28 at DAL. **c**


Representative genome browser tracks showing examples of DAL. A black arrow indicates a locus identified as differentially accessible. DAL are covered with H3K9me3 as indicated by the H3K9me3 ChIP-seq tracks.

**FigureS11:**



**Figure S11:** **a** Metaplot showing ATAC-seq read coverage at all MORC3 peaks. **b,c** Metaplots and heatmaps showing ATAC-seq read coverage at MORC3 bound promoters (**b**) and at MORC3 bound IAPEz-int (**c**) in WT and *Morc3<sup>MD41/MD41</sup>*.

**Figure S12:**



**Figure S12:** TRIM28 ChIP-qPCR to validate the presence of TRIM28 at the *Mest* and *Nnat*. MERVL-LTR and MERVL-pol loci were used as negative control of the TRIM28 ChIP-qPCR. TRIM28 ChIP-qPCR was performed at DALs IAPEz-int and LTRIS2.